{
  "pathway_name": "ampullary-cancer-clinical-pathways-v3-2024",
  "original_file": "ampullary-cancer-clinical-pathways-v3-2024_extracted.json",
  "processed_at": "2025-03-29T00:56:55.130454",
  "complete_summary": {
    "response": "# COMPREHENSIVE CLINICAL PATHWAY FOR AMPULLARY CANCER (V3 2024)\n\n## I. INITIAL EVALUATION AND DIAGNOSIS\n\n### Initial Assessment\n- **Presentation**: Suspicious lesion or biopsy-proven ampullary cancer\n- **Initial Sampling**:\n  - Sample mass using biopsy forceps\n  - If inadequate/non-diagnostic \u2192 EUS with fine needle aspiration or core biopsy\n\n### Staging Procedures\n- **Imaging**: Contrast-enhanced CT of chest, abdomen, and pelvis (multiphase preferred)\n- **Additional Staging**: EUS staging considered case-by-case\n- **Metastatic Disease Assessment**: Critical decision point for treatment pathway selection\n\n### VA Presumptive Service Connection\nAmpullary cancer may qualify for VA presumptive service connection under:\n1. **Atomic Veterans \u2013 Ionizing Radiation Exposure**\n   - Qualifying condition: Cancer of small intestine, pancreas, and bile ducts\n2. **Gulf War and Post 9/11 Veterans**\n   - For service on/after September 11, 2001 in specified locations\n   - For service on/after August 2, 1990 in Southwest Asia theater\n   - Qualifying condition: Any gastrointestinal cancer\n\n## II. MOLECULAR TESTING FRAMEWORK\n\n### Universal Testing Requirements\n- **Pharmacogenomic Testing**\n  - DPYD testing (blood/saliva specimen)\n  - Required before any fluoropyrimidine-based therapy\n  - Critical for detecting patients at risk for fluoropyrimidine toxicity\n  \n- **Germline Testing**\n  - Germline NGS Panel including minimum genes: BRCA1, BRCA2, ERCC5, MEN1, MSH3, CHEK1, TP53, APC, FANCA, ERBB2, RTEL1, HNF1A, PTCH1, ATM, RAD50, MUTYH and Lynch genes\n\n### Disease-Specific Testing\n\n#### For Resectable Disease:\n- MMR testing by IHC (\u00b1MSI by PCR)\n- MSI testing by PCR (\u00b1MMR by IHC)\n\n#### For Stage IV/Unresectable Disease:\n- Comprehensive Genomic Profiling (CGP)\n- MMR testing by IHC\n- HER2 testing pathway:\n  - IHC for HER2 \u2192 If IHC score 2+, reflex to FISH testing\n\n#### When Adequate Tumor Tissue Unavailable:\n- If rebiopsy feasible \u2192 Rebiopsy for CGP, MMR, and HER2 status\n- If rebiopsy not feasible \u2192 Proceed with liquid biopsy\n\n## III. TREATMENT PATHWAYS\n\n### A. Completely Resected (R0) Ampullary Cancer\n\n#### 1. Intestinal Subtype\n- **Characteristics**: Cigar-shaped nuclei, pseudostratified columnar cells, complex glandular structure\n- **Biomarkers**: More likely CK20+, CDX2+; less likely MUC1+, CK7+\n- **Treatment Decision Point**: Oxaliplatin candidate? (Criteria: ECOG PS 0-1, no prohibitive neuropathy)\n  - **If YES**: mFOLFOX6 or CAPOX\n  - **If NO**: Fluorouracil or capecitabine\n\n#### 2. Pancreaticobiliary/Mixed Subtype\n- **Characteristics**: Rounded/cuboidal nuclei, well-spaced simple glands, desmoplasia\n- **Biomarkers**: More likely MUC1+, CK7+; less likely CDX2+, CK20+\n- **Treatment Decision Point**: mFOLFIRINOX candidate? (Criteria: ECOG PS 0-1, no uncontrolled CAD, no prohibitive neuropathy)\n  - **If YES**: mFOLFIRINOX (for 6 months)\n  - **If NO**: Gemcitabine and capecitabine\n\n### B. Stage IV/Unresectable Pancreaticobiliary or Mixed Subtype\n\n#### 1. First-Line Treatment (Fit for Chemotherapy)\n- **Treatment Decision Point**: mFOLFIRINOX candidate?\n  - **If YES**:\n    - mFOLFIRINOX\n    - Monitor for progression/toxicity\n      - If progression/toxicity: Assess molecular alterations\n        - If dMMR \u2192 Pembrolizumab\n        - If other targetable alterations \u2192 Precision Oncology Consult\n        - If no molecular alterations \u2192 Nab-paclitaxel and gemcitabine\n  - **If NO**:\n    - Nab-paclitaxel and gemcitabine\n    - Monitor for progression/toxicity\n      - If progression/toxicity: Assess molecular alterations\n        - If dMMR \u2192 Pembrolizumab\n        - If other targetable alterations \u2192 Precision Oncology Consult\n        - If no molecular alterations \u2192 mFOLFOX6 or CAPOX\n\n#### 2. Subsequent Line Treatment\nOptions include:\n- **Fluoropyrimidine-Based Regimens**: mFOLFOX6 or FOLFIRI\n- **Gemcitabine-Based Regimens**:\n  - Gemcitabine single agent\n  - Gemcitabine + cisplatin (preferred)\n  - Gemcitabine + carboplatin\n- **Targeted Therapy**: Consider Precision Oncology consult, especially for BRAF V600E or KRAS G12C mutations\n\n### C. Stage IV Intestinal Subtype\n\n#### 1. First-Line Treatment (Fit for Combination Chemotherapy)\n- **Treatment Decision Point**: Oxaliplatin candidate?\n  - **If YES**:\n    - Follow molecular testing pathway\n    - Assess bevacizumab candidacy\n      - If candidate: mFOLFOX6 or CAPOX \u00b1 bevacizumab\n      - If not candidate: mFOLFOX6 or CAPOX\n  - **If NO**:\n    - Assess bevacizumab candidacy\n      - If candidate: FOLFIRI + bevacizumab\n      - If not candidate: FOLFIRI alone\n\n#### 2. Second-Line Treatment\n- **If HER2 IHC 3+**: Fam-trastuzumab deruxtecan-nxki\n- **If dMMR**: Pembrolizumab\n- **If No targetable alterations**:\n  - Prior oxaliplatin-based therapy \u2192 FOLFIRI \u00b1 bevacizumab\n  - Prior irinotecan-based therapy \u2192 Assess oxaliplatin candidacy\n    - If candidate: mFOLFOX6 or CAPOX \u00b1 bevacizumab\n    - If not candidate: Gemcitabine\n\n### D. Stage IV (Unfit for Combination Chemotherapy)\n- Follow molecular testing pathway and refer to Palliative Care\n- **Treatment Decision Point**: Actionable molecular alteration present?\n  - **If YES**:\n    - dMMR \u2192 Pembrolizumab\n    - Other alterations \u2192 Precision Oncology Consult\n  - **If NO**: Treatment based on histological subtype\n    - Intestinal subtype \u2192 Fluorouracil or Capecitabine (after DPYD testing)\n    - Pancreatic/biliary subtype \u2192 Gemcitabine\n\n## IV. SPECIAL CONSIDERATIONS\n\n### Bevacizumab Eligibility Criteria\n- **Requirements**: ECOG PS 0-2, ANC > 1500/mm\u00b3\n- **Contraindications**:\n  - Non-healing wound/fracture\n  - Major surgery within prior 4 weeks\n  - Bleeding disorder or coagulopathy\n  - Recent GI perforation\n  - Unstable cardiac condition\n  - Active cocaine use\n\n### Capecitabine Restrictions\n- Avoid if:\n  - Adherence issues present\n  - Unable to self-report toxicity\n  - Severe renal impairment (CrCl <30ml/min)\n\n### DPYD Testing Protocol\n- If results indicate intermediate/poor metabolizer \u2192 Pharmacogenomics consultation required\n- Withholding chemotherapy awaiting results may be dangerous if disease burden is high\n\n### Clinical Trial Consideration\n- Clinical trials should always be considered at every decision point\n- Contact resource: CancerClinicalTrialsNavigation@va.gov\n\n## V. KEY DEFINITIONS AND ABBREVIATIONS\n\n- **CGP**: Comprehensive Genomic Profiling\n- **DPYD**: Dihydropyrimidine Dehydrogenase\n- **dMMR**: Deficient Mismatch Repair\n- **EUS**: Endoscopic Ultrasound\n- **FOLFIRI**: Fluorouracil, Leucovorin, and Irinotecan\n- **FOLFOX**: Fluorouracil, Leucovorin, and Oxaliplatin\n- **CAPOX**: Capecitabine and Oxaliplatin\n- **IHC**: Immunohistochemistry\n- **MMR**: Mismatch Repair\n- **MSI**: Microsatellite Instability\n\nThis pathway represents best practices for ampullary cancer management according to the 2024 (v3) guidelines, with individualization based on specific patient factors always warranted.",
    "thinking": "I'll summarize the entire Ampullary Cancer Clinical Pathway based on the detailed analyses provided from pages 2-12. This will require synthesizing all the information into a comprehensive, structured clinical pathway that covers all aspects of evaluation, diagnosis, treatment, and monitoring.\n\n# Comprehensive Summary of Ampullary Cancer Clinical Pathway\n\n## 1. Overview and Initial Assessment\n\n### Initial Presentation and Diagnosis\n- Starting point: Suspicious lesion or biopsy-proven ampullary cancer\n- For suspicious lesions: Sample mass using biopsy forceps\n- If sample inadequate/non-diagnostic \u2192 EUS with fine needle aspiration or core biopsy\n\n### Staging Procedures\n- Contrast-enhanced CT of chest, abdomen, and pelvis (multiphase preferred)\n- EUS staging can be considered case-by-case\n\n### VA Presumptive Service Connection\nFor veterans, ampullary cancer may qualify for presumptive service connection under:\n1. **Atomic Veterans \u2013 Exposure to Ionizing Radiation**\n   - Qualifying condition: Cancer of small intestine, pancreas, and bile ducts (applies to ampullary cancer)\n\n2. **Gulf War and Post 9/11 Veterans**\n   - For service on/after September 11, 2001 in: Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen\n   - For service on/after August 2, 1990 in: Southwest Asia theater of operations or Somalia\n   - Qualifying condition: Any gastrointestinal cancer (includes ampullary cancer)\n\n### Definition of Southwest Asia Theater of Operations\n- Iraq, Kuwait, Saudi Arabia\n- The neutral zone between Iraq and Saudi Arabia\n- Bahrain, Qatar, United Arab Emirates, Oman\n- Gulf of Aden, Gulf of Oman, Persian Gulf, Arabian Sea, Red Sea\n- Airspace above these locations\n\n## 2. Molecular Testing Protocol\n\n### Required Testing for All Patients\n- **Pharmacogenomic Testing**\n  - DPYD testing using blood or saliva specimen (Vendor: Fulgent)\n  - Required before any fluoropyrimidine-based therapy\n  - If DPYD PCx results indicate intermediate or poor metabolizer, consult pharmacogenomics for dose adjustment\n  - Note: Withholding chemotherapy for 2-3 weeks without DPYD results may endanger patient with high disease burden\n\n- **Germline Testing**\n  - Germline NGS Panel using blood or saliva specimen (Vendors: Fulgent, Prevention Genetics)\n  - Includes minimum genes: BRCA1, BRCA2, ERCC5, MEN1, MSH3, CHEK1, TP53, APC, FANCA, ERBB2, RTEL1, HNF1A, PTCH1, ATM, RAD50, MUTYH and Lynch genes (EPCAM2, MLH1, MSH2, MSH6, PMS2)\n\n### Testing Based on Disease Status\n\n#### For Completely Resectable Disease:\n- **Immunohistochemistry (IHC)**\n  - MMR testing by IHC (with or without MSI by PCR)\n  - Requires tumor tissue specimen\n\n- **Molecular Testing**\n  - MSI testing by PCR (with or without MMR by IHC)\n  - Requires tumor tissue specimen\n\n#### For Stage IV or Unresectable Disease:\n- **Somatic Testing**\n  - Comprehensive Genomic Profiling (CGP)\n  - Vendors: Foundation, Tempus\n  - Requires tumor tissue or blood specimen\n\n- **Immunohistochemistry (IHC)**\n  - MMR testing by IHC\n  - Requires tumor tissue specimen\n\n- **HER2 Testing**\n  - IHC for HER2\n  - If IHC score is 2+, reflex to FISH testing\n  - Requires tumor tissue specimen\n\n### If Adequate Tumor Tissue Unavailable:\n- **Decision point**: Is rebiopsy feasible?\n  - If YES: Rebiopsy primary or metastatic site \u2192 Perform CGP, MMR, and HER2 status\n  - If NO: Proceed with liquid biopsy\n\n## 3. Treatment Pathway: Initial Evaluation and Decision Tree\n\n### Metastatic Disease Assessment\n- **First Decision Point**: Is metastatic disease present?\n\n#### If Metastatic Disease Present (YES):\n- Proceed to biopsy as clinically appropriate:\n  - Preferred: At least two attempts at core biopsy of metastatic lesion\n  - If not feasible: Sample primary ampullary mass\n  - If sample inadequate: EUS with fine needle aspiration/core biopsy\n  - Include cell block for molecular testing\n\n- **Subtype Determination**:\n  - If Intestinal type \u2192 Follow Intestinal Subtype Stage IV pathway\n  - If Non-intestinal type \u2192 Follow Pancreaticobiliary or Mixed Subtype Stage IV pathway\n\n#### If No Metastatic Disease (NO):\n- Proceed to Pancreaticoduodenectomy\n- Follow the Completely Resected (R0), Adjuvant Treatment pathway\n\n## 4. Treatment Pathway: Completely Resected (R0) Disease\n\n### Initial Assessment\n- DPYD testing required before proceeding with adjuvant treatment\n\n### Primary Decision Point: Intestinal Subtype Determination\nBased on morphology with IHC confirmation:\n\n#### If Intestinal Subtype (YES):\n- Characteristics: \n  - Cigar-shaped nuclei, pseudostratified columnar cells, complex/cribriform glandular structure, intraluminal necrosis\n  - Biomarkers: More likely to express CK20 and CDX2, less likely to express MUC1 and CK7\n\n- **Assessment for Oxaliplatin Candidacy**:\n  - Criteria: ECOG PS 0-1, lack of prohibitive neuropathy\n  \n  - **If Candidate for Oxaliplatin (YES)**:\n    - Treatment: mFOLFOX6 or CAPOX\n  \n  - **If Candidate for Oxaliplatin (NO)**:\n    - Treatment: Fluorouracil or capecitabine\n\n#### If Intestinal Subtype (NO) - Pancreaticobiliary Type:\n- Characteristics:\n  - Rounded/cuboidal nuclei, well-spaced simple glands, desmoplasia\n  - Biomarkers: More likely to express MUC1 and CK7, less likely to express CDX2 and CK20\n\n- **Assessment for mFOLFIRINOX Candidacy**:\n  - Criteria: ECOG PS 0-1, absence of uncontrolled CAD, lack of prohibitive neuropathy, AND\n  - Patient commitment to lab draws, 14-day clinic visits, and utilizing ambulatory infusion pump\n  \n  - **If Candidate for mFOLFIRINOX (YES)**:\n    - Treatment: mFOLFIRINOX (for 6 months)\n  \n  - **If Candidate for mFOLFIRINOX (NO)**:\n    - Treatment: Gemcitabine and capecitabine\n\n## 5. Treatment Pathway: Stage IV Pancreaticobiliary or Mixed Subtype\n\n### Initial Assessment\n- DPYD testing required before proceeding\n- Starting point: Patient fit for chemotherapy\n\n### Primary Decision Path: Assessment for mFOLFIRINOX Candidacy\n- **Criteria**: \n  - ECOG PS 0-1\n  - Absence of uncontrolled CAD\n  - No prohibitive neuropathy\n  - Patient commitment to bi-weekly clinic visits\n  - Ability to utilize ambulatory infusion pump\n\n#### If Patient IS a mFOLFIRINOX Candidate:\n1. Two initial options:\n   - Follow Molecular Testing pathway\n   - Refer to Palliative Care\n2. If proceeding with treatment \u2192 mFOLFIRINOX\n3. Monitor for progression or unmanageable toxicity\n   - **If progression/toxicity occurs**:\n     - Assess for molecular alterations:\n       - If dMMR \u2192 Pembrolizumab\n       - If other targetable alterations (BRAF V600E, IDH mutation, FGFR2 fusion, NTRK fusion, HER-2 overexpression) \u2192 Precision Oncology Consult\n       - If no molecular alterations \u2192 Nab-paclitaxel and gemcitabine\n   - **If no progression/toxicity**: Continue therapy as tolerated\n\n#### If Patient is NOT a mFOLFIRINOX Candidate:\n1. First-line treatment: Nab-paclitaxel and gemcitabine\n2. Monitor for progression or unmanageable toxicity\n   - **If progression/toxicity occurs**:\n     - Assess for molecular alterations:\n       - If dMMR \u2192 Pembrolizumab\n       - If other targetable alterations \u2192 Precision Oncology Consult\n       - If no molecular alterations \u2192 mFOLFOX6 or CAPOX\n   - **If no progression/toxicity**: Continue chemotherapy as tolerated\n\n### Subsequent Line Treatment for Pancreaticobiliary or Mixed Subtype\nWhen progression occurs on first-line therapy, options include:\n\n1. **Fluoropyrimidine-Based Regimens** (requires DPYD testing)\n   - mFOLFOX6 regimen\n   - FOLFIRI regimen\n\n2. **Gemcitabine-Based Regimens**\n   - Gemcitabine single agent\n   - Gemcitabine + cisplatin (preferred)\n   - Gemcitabine + carboplatin\n   - Can be followed by fluorouracil or capecitabine\n\n3. **Targeted Therapy Approach**\n   - Consider Precision Oncology consult, particularly for:\n     - BRAF V600E mutations\n     - KRAS G12C mutations\n\n## 6. Treatment Pathway: Stage IV Intestinal Subtype\n\n### First Line Treatment\n- **Initial Assessment**:\n  - DPYD testing required\n  - Patient assessed as fit for combination chemotherapy\n\n- **Oxaliplatin Eligibility Assessment**:\n  - **Contraindications**:\n    - Any adjuvant treatment within past 12 months\n    - Pre-existing neuropathy >grade 1\n    - Patient preference to avoid neuropathy\n\n  - **If CANDIDATE for Oxaliplatin**:\n    1. Follow molecular testing pathway\n    2. Assess bevacizumab candidacy\n       - **If candidate for bevacizumab**:\n         - Treatment: mFOLFOX6 or CAPOX with or without bevacizumab\n       - **If NOT candidate for bevacizumab**:\n         - Treatment: mFOLFOX6 or CAPOX\n\n  - **If NOT CANDIDATE for Oxaliplatin**:\n    1. Assess bevacizumab candidacy\n       - **If candidate for bevacizumab**:\n         - Treatment: FOLFIRI and bevacizumab\n       - **If NOT candidate for bevacizumab**:\n         - Treatment: FOLFIRI alone\n\n  - **Bevacizumab Eligibility Criteria**:\n    - ECOG Performance Status 0-2\n    - ANC > 1500/mm\u00b3\n    - **Contraindications**:\n      - Non-healing wound/fracture\n      - Major surgery within prior 4 weeks\n      - Bleeding disorder or coagulopathy\n      - Recent history of GI perforation\n      - Unstable cardiac condition (uncontrolled HTN, arterial thromboembolism, symptomatic CHF, arrhythmia)\n      - Active cocaine use\n\n### Second Line Treatment\n- **Initial Assessment**:\n  - DPYD testing if not already performed\n  - Follow Molecular Testing pathway and consider Palliative Care referral\n\n- **Molecular Testing Assessment**:\n  - **If HER2 IHC 3+**: \n    - Treatment: Fam-trastuzumab deruxtecan-nxki\n    - Note: HER2 IHC confirmation recommended if amplification call is not from NPOP-approved vendor\n\n  - **If dMMR (Deficient Mismatch Repair)**:\n    - Treatment: Pembrolizumab\n\n  - **If No targetable alterations**:\n    - Treatment depends on prior first-line regimen\n\n    - **If prior first-line was Oxaliplatin-based**:\n      - Treatment: FOLFIRI with or without bevacizumab\n\n    - **If prior first-line was Irinotecan-based**:\n      - Assess if candidate for oxaliplatin\n        - **If Yes**: mFOLFOX6 or CAPOX with or without bevacizumab\n        - **If No**: Gemcitabine\n\n## 7. Treatment Pathway: Stage IV, Unfit for Combination Chemotherapy\n\n### Initial Management\n- Follow Molecular Testing pathway\n- Refer to Palliative Care\n\n### Treatment Decision Based on Molecular Testing\n- **If Actionable molecular alteration present**:\n  - dMMR \u2192 Treatment with Pembrolizumab\n  - Other molecular alterations \u2192 Precision Oncology Consult\n\n- **If No actionable molecular alterations**, treatment based on histological subtype:\n  - **Intestinal subtype**:\n    - Perform DPYD testing\n    - Treatment: Fluorouracil or Capecitabine\n\n  - **Pancreatic or biliary subtype**:\n    - Treatment: Gemcitabine\n\n- **Second Line Therapy**:\n  - Consider if patient is intolerant to or has progressed on first-line treatment\n\n## 8. Additional Clinical Considerations\n\n### Capecitabine Contraindications\n- Adherence issues\n- Inability to self-report toxicity\n- Severe renal impairment (CrCl <30 ml/min)\n\n### Clinical Trials\n- Clinical trials should always be considered at any point in the pathway\n- For assistance finding a clinical trial, contact: CancerClinicalTrialsNavigation@va.gov\n\n### Abbreviations & Definitions\n- **CGP**: Comprehensive Genomic Profiling\n- **DPYD**: Dihydropyrimidine Dehydrogenase\n- **dMMR**: Deficient Mismatch Repair\n- **EUS**: Endoscopic Ultrasound\n- **FOLFIRI**: Fluorouracil, Leucovorin, and Irinotecan\n- **FOLFOX**: Fluorouracil, Leucovorin, and Oxaliplatin\n- **CAPOX**: Capecitabine and Oxaliplatin\n- **IHC**: Immunohistochemistry\n- **MMR**: Mismatch Repair\n- **MSI**: Microsatellite Instability\n- **PCR**: Polymerase Chain Reaction\n\nLet me now check this summary for completeness and ensure that all key aspects of the clinical pathway are included. I'll then organize it into a comprehensive summary."
  }
}